# Allogeneic UCB-derived CAR-T for SLE

> **NCT07274059** · EARLY_PHASE1 · RECRUITING · sponsor: **Chengdu Ucello Biotechnology Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- SLE - Systemic Lupus Erythematosus

## Interventions

- **DRUG:** allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA

## Key facts

- **NCT ID:** NCT07274059
- **Lead sponsor:** Chengdu Ucello Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-26
- **Primary completion:** 2035-12-31
- **Final completion:** 2037-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07274059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07274059, "Allogeneic UCB-derived CAR-T for SLE". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07274059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*